Literature DB >> 11251344

Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke.

A S Gallus1.   

Abstract

Clinical trials and meta-analyses have shown that low-molecular-weight heparin and unfractionated heparin are effective in preventing deep vein thrombosis (DVT) in acutely ill medical inpatients who are at risk as they are likely to be bedridden for 6 days or more. It is not known, however, if such prophylaxis can also reduce the likelihood of fatal pulmonary embolism or decrease all-causes mortality in this patient population. No recommendations can be made regarding thromboprophylaxis in those at a lower risk of venous thromboembolism or in short-stay inpatients, as these have not yet undergone clinical trial. Current evidence suggests that high doses of heparin should be avoided after an acute ischaemic stroke, as the results of recent large trials suggest any potential treatment benefit in preventing DVT is cancelled by the increased intracranial bleeding risk caused from the underlying disease. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11251344     DOI: 10.1159/000054166

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  2 in total

1.  M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice.

Authors:  Subrata Chakrabarti; Lea M Beaulieu; Lara A Reyelt; Mark D Iafrati; Jane E Freedman
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

2.  Pulmonary embolism after brain hemorrhage in a hypertensive patient: the therapeutic dilemma.

Authors:  Carlo Oneglia; Anna Gualeni
Journal:  J Thromb Thrombolysis       Date:  2007-05-30       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.